Tag: executives

SAN DIEGO, Aug. 10, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage’s July 2024 initial public offering (the “IPO”), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage as well as certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933.

SANTO DOMINGO, Dominican Republic, Aug. 08, 2025 (GLOBE NEWSWIRE) -- On Tuesday, August 12th, the Dominican Republic is celebrating the National Free Zone's Day with a high-level event organized by the Ministry of Industry, Commerce and MSMEs (MICM), in collaboration with the National Free Zones Council and the Dominican Association of Free Zones (ADOZONA). The event aims to commemorate the achievements of the free zone regime and to highlight the sector’s crucial economic and social contributions to the country.

Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

GROSSE POINTE FARMS, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Saga Communications, Inc. (Nasdaq - SGA) (the “Company” or “Saga”) today reported that net revenue decreased 5.0% to $28.2 million for the quarter ended June 30, 2025 compared to $29.7 million for the same period last year. Station operating expense decreased 4.6% for the quarter to $22.2 million compared to the same period last year. For the quarter, operating income was $1.4 million compared to $2.1 million for the same quarter last year and station operating income (a non-GAAP financial measure) decreased 6.4% to $6.0 million. Capital expenditures were $1.3 million for the quarter compared to $1.5 million for the same period last year. We had net income of $1.1 million for the quarter compared to net income of $2.5 million for the second quarter last year. Diluted earnings per share were $0.18 in the second quarter of 2025.